Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reflections on the Optimal Use of eDiaries for Data Collection in Vaccine Clinical Trials.

Journal of medical Internet research·2025
Same author

Lessons Learned From Characterizing Long COVID Among US Medicare Beneficiaries.

Pharmacoepidemiology and drug safety·2025
Same author

Relative Effectiveness and Waning of a Third Dose of mRNA COVID-19 Vaccine in Medicare Beneficiaries Aged 65 Years and Older During the BA.1/BA.2 Omicron Period.

The Journal of infectious diseases·2024
Same author

Real-world Effectiveness of mRNA COVID-19 Vaccines Among US Nursing Home Residents Aged ≥65 Years in the Pre-Delta and High Delta Periods.

Open forum infectious diseases·2024
Same author

Transfusion-transmitted <i>Babesia</i> spp.: a changing landscape of epidemiology, regulation, and risk mitigation.

Journal of clinical microbiology·2023
Same author

COVID-19 convalescent plasma donors: Unique motivations in unique times?

Transfusion·2023

Related Experiment Video

Updated: May 16, 2026

High Yield Purification of Plasmodium falciparum Merozoites For Use in Opsonizing Antibody Assays
10:38

High Yield Purification of Plasmodium falciparum Merozoites For Use in Opsonizing Antibody Assays

Published on: July 17, 2014

Analyzing actual risk in malaria-deferred donors through selective serologic testing.

Megan L Nguyen1, Tami Goff, Joan Gibble

  • 1Transmissible Diseases Department, American Red Cross Holland Laboratory, Rockville, Maryland 20855, USA. Megan.Nguyen@redcross.org

Transfusion
|December 11, 2012
PubMed
Summary

US blood donors deferred for malaria risk, especially those traveling to Mexico, were tested for Plasmodium infection. Results show no infections acquired in Mexico, suggesting relaxed deferral policies for low-risk travel. A history of malaria is a better deferral criterion.

More Related Videos

Isolation and Analysis of Brain-sequestered Leukocytes from Plasmodium berghei ANKA-infected Mice
12:48

Isolation and Analysis of Brain-sequestered Leukocytes from Plasmodium berghei ANKA-infected Mice

Published on: January 2, 2013

A Multi-detection Assay for Malaria Transmitting Mosquitoes
09:00

A Multi-detection Assay for Malaria Transmitting Mosquitoes

Published on: February 28, 2015

Related Experiment Videos

Last Updated: May 16, 2026

High Yield Purification of Plasmodium falciparum Merozoites For Use in Opsonizing Antibody Assays
10:38

High Yield Purification of Plasmodium falciparum Merozoites For Use in Opsonizing Antibody Assays

Published on: July 17, 2014

Isolation and Analysis of Brain-sequestered Leukocytes from Plasmodium berghei ANKA-infected Mice
12:48

Isolation and Analysis of Brain-sequestered Leukocytes from Plasmodium berghei ANKA-infected Mice

Published on: January 2, 2013

A Multi-detection Assay for Malaria Transmitting Mosquitoes
09:00

A Multi-detection Assay for Malaria Transmitting Mosquitoes

Published on: February 28, 2015

Area of Science:

  • Infectious Diseases
  • Epidemiology
  • Blood Transfusion Safety

Background:

  • Millions of US blood donors face annual deferral due to travel to malaria-endemic regions.
  • Many deferred donors travel to low-risk areas like Mexico, not high-risk regions associated with transfusion-transmitted malaria (TTM).
  • This study investigates Plasmodium infection rates in malaria-deferred donors, focusing on those who traveled to Mexico.

Purpose of the Study:

  • To assess the risk of Plasmodium infection among US blood donors deferred for malaria risk, particularly those with travel history to Mexico.
  • To evaluate the effectiveness of current malaria deferral policies for blood donors.
  • To inform potential policy changes regarding blood donation eligibility for travelers to low-risk areas.

Main Methods:

  • Blood samples were collected from malaria-deferred donors and tested for Plasmodium antibodies using enzyme immunoassay (EIA).
  • Repeat-reactive (RR) EIA samples were further analyzed using real-time polymerase chain reaction (PCR).
  • Donors completed questionnaires detailing travel history, residence, and previous malaria diagnoses.

Main Results:

  • Out of 5610 malaria-deferred donors tested, 88 (1.6%) were EIA repeat-reactive (RR); none were PCR positive.
  • Of 1121 donors who traveled to Mexico, most visited low-risk areas (Quintana Roo); only 2.2% visited moderate/high-risk regions.
  • Two Mexican travelers tested RR, but both had prior malaria infections unrelated to their Mexico travel.

Conclusions:

  • Travel to Mexico accounts for a significant portion of malaria-related donor deferrals, yet these donors typically visit low-risk areas.
  • No evidence of malaria acquired in Mexico was found, supporting existing risk assessments for this region.
  • Revising deferral policies to permit donations from travelers to low-risk Mexican areas and deferring all individuals with a history of malaria could enhance TTM prevention.